MedTrace Logo

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

NCT00550420 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2017-11-08

Study results available
· View outcomes & findings →

Summary

This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640. All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment. The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed AVA105640. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status

Conditions

Interventions

DRUG

Rosiglitazone XR

experimental drug

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
51 Years
Max Age
91 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-01
Primary Completion
2009-02-12
Completion
2009-02-12

Countries

  • United States
  • Austria
  • Bulgaria
  • Chile
  • China
  • Croatia
  • Estonia
  • Germany
  • Greece
  • Hungary
  • Mexico
  • New Zealand
  • Peru
  • Philippines
  • Puerto Rico
  • Russia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00550420 on ClinicalTrials.gov